Lotus Eye Hospital and Institute Limited Stock Price Today (NSE: LOTUSEYE)
Fundamental Score
Lotus Eye Hospital and Institute Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lotus Eye Hospital and Institute Limited share price today is ₹108.77, down 0.28% on NSE/BSE as of 2 September 2026. Lotus Eye Hospital and Institute Limited (LOTUSEYE) is a Small-cap company in the Hospital sector with a market capitalisation of ₹250.74 (Cr). The 52-week high for LOTUSEYE share price is ₹147.00 and the 52-week low is ₹97.59. At a P/E ratio of 1679.44x, LOTUSEYE is currently trading above its industry average P/E of 48.79x. The company has a Return on Equity (ROE) of 0.13% and a debt-to-equity ratio of 0.19.
Lotus Eye Hospital and Institute Limited Share Price Chart — NSE/BSE Historical Performance
Lotus Eye Hospital and Institute Limited share price chart: -4.41% return over the past month. 52-week high ₹147.00, 52-week low ₹97.59.
Lotus Eye Hospital and Institute Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹116.07 | ₹116.49 | ₹112.30 | ₹113.99 | 18.14K (Cr) | |
| ₹116.00 | ₹118.47 | ₹115.06 | ₹116.07 | 6.89K (Cr) | |
| ₹117.50 | ₹118.20 | ₹115.00 | ₹115.22 | 9.92K (Cr) | |
| ₹117.99 | ₹118.00 | ₹116.20 | ₹116.61 | 5.52K (Cr) | |
| ₹119.80 | ₹119.80 | ₹116.10 | ₹117.62 | 8.97K (Cr) | |
| ₹116.95 | ₹122.00 | ₹116.37 | ₹119.78 | 34.71K (Cr) | |
| ₹116.00 | ₹118.55 | ₹115.21 | ₹115.61 | 13.83K (Cr) | |
| ₹117.24 | ₹119.00 | ₹115.86 | ₹118.82 | 13.17K (Cr) | |
| ₹117.01 | ₹118.49 | ₹116.70 | ₹117.24 | 2.46K (Cr) | |
| ₹117.85 | ₹118.20 | ₹116.05 | ₹117.83 | 9.01K (Cr) |
Lotus Eye Hospital and Institute Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹122.00 | ₹122.00 | ₹112.30 | ₹113.99 | -6.57% | |
| ₹116.82 | ₹131.98 | ₹115.46 | ₹117.51 | +0.59% | |
| ₹106.30 | ₹143.20 | ₹106.30 | ₹116.82 | +9.90% | |
| ₹117.55 | ₹121.06 | ₹101.02 | ₹108.57 | -7.64% | |
| ₹99.01 | ₹129.79 | ₹99.01 | ₹118.87 | +20.06% | |
| ₹109.48 | ₹113.07 | ₹97.59 | ₹98.22 | -10.28% | |
| ₹127.00 | ₹136.71 | ₹106.01 | ₹110.19 | -13.24% | |
| ₹119.58 | ₹147.00 | ₹104.50 | ₹135.27 | +13.12% | |
| ₹103.61 | ₹138.00 | ₹101.50 | ₹119.24 | +15.09% | |
| ₹127.00 | ₹133.00 | ₹102.11 | ₹105.65 | -16.81% | |
| ₹121.00 | ₹127.00 | ₹113.43 | ₹125.03 | +3.33% | |
| ₹116.99 | ₹139.20 | ₹107.46 | ₹118.49 | +1.28% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Overvalued micro-cap eye care play with poor profitability and high liquidity risk; avoid until fundamentals improve.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Lotus Eye Hospital decided not to proceed with the voluntary delisting from NSE. Sangeetha Sundaramoorthy acquired a 6.87% stake from Kavetha Sundaramoorthy for approximately million.
CORE STORY (THE REAL GAME)
- Stake acquisition by promoter
- Delisting proposal (now withdrawn) caused volatility
- Modest revenue growth but declining profits
- Successful acquisitions
- Significant improvement in profitability
- Favorable regulatory changes in the healthcare sector
- Micro-cap illiquidity
- High P/E relative to industry
- Low ROE and ROCE
- Decreasing promoter holding over the last 3 years
FII: 0.0% (Δ -0.01%) indicates lack of institutional interest. Promoter increased stake by 0.25%, a mildly positive signal.
India's hospital sector is expected to grow at a CAGR of up to 12% over the next 3-5 years, a potential tailwind.
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order on March 4, 2026. Specifics of the order not found after live search.
No: Free Cash Flow 5Y: ₹1.67 Cr.
Next 3-6 months hinge on execution. If they can't demonstrate improved profitability, expect a correction. Key is to monitor cash flow and ROE.
Primary Thesis Risk
Inability to scale operations and improve profitability will lead to significant downside.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Lotus Eye Hospital and Institute Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lotus Eye Hospital and Institute Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LOTUSEYE across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Strong Revenue Growth (26.19%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.19)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Risk Factors
10 factors identified
Below-Average Return on Equity (0.13%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (1.19%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 1679.44x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-39.90% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-44.79% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (0.94x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-10.98 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (87.15%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Lotus Eye Hospital and Institute Limited vs Hospital Peers
Peer Comparison - Hospital
Compare Lotus Eye Hospital and Institute Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Lotus Eye Hospital and Institute LimitedLotus Eye Hospi...Selected✓ LOTUSEYE • 532998 | 2.1/100 | ₹108.77₹109 | ₹250.74₹250.74 | 1679.44Average 1679.4 Average | 0.13%Poor 0.13% Poor | 1.19%Poor 1.19% Poor | 0.19Excellent 0.2 Excellent | -44.79%Poor -44.79% Poor | 10.66%Good 10.66% Good | 0.00% |
Apollo Hospitals Enterprise LimitedApollo Hospital... APOLLOHOSP • 508869 | 62.1/100 | ₹8817.00₹8817 | ₹128448.55₹128448.55 | 61.47Average 61.5 Average | 21.95%Excellent 21.95% Excellent | 19.28%Good 19.28% Good | 0.60Good 0.6 Good | 66.81%Excellent 66.81% Excellent | 19.03%Excellent 19.03% Excellent | 0.22% |
Max Healthcare Institute LimitedMax Healthcare ... MAXHEALTH • 543220 | 56.9/100 | ₹1014.40₹1014 | ₹107422.79₹107422.79 | 73.71Average 73.7 Average | 14.33%Average 14.33% Average | 13.43%Average 13.43% Average | 0.32Excellent 0.3 Excellent | — — | 27.30%Excellent 27.30% Excellent | 0.18% |
Fortis Healthcare LimitedFortis Healthca... FORTIS • 532843 | 56.8/100 | ₹916.70₹917 | ₹73687.64₹73687.64 | 70.32Average 70.3 Average | 11.08%Average 11.08% Average | 12.83%Average 12.83% Average | 0.29Excellent 0.3 Excellent | — — | 17.76%Excellent 17.76% Excellent | 0.10% |
Aster DM Quality Care LimitedAster DM Qualit... ASTERDM • 540975 | 37.2/100 | ₹818.00₹818 | ₹71917.90₹71917.90 | 225.67Average 225.7 Average | 9.70%Poor 9.70% Poor | 11.35%Average 11.35% Average | 0.15Excellent 0.2 Excellent | 21.31%Excellent 21.31% Excellent | -11.61%Poor -11.61% Poor | 0.61% |
Narayana Hrudayalaya Ltd.Narayana Hruday... NH • 539551 | 68.3/100 | ₹1803.00₹1803 | ₹41592.95₹41592.95 | 50.96Average 51.0 Average | 19.74%Good 19.74% Good | 14.53%Average 14.53% Average | 1.07Average 1.1 Average | — — | 25.05%Excellent 25.05% Excellent | 0.22% |
Global Health LimitedGlobal Health L... MEDANTA • 543654 | 59.9/100 | ₹1442.70₹1443 | ₹35993.93₹35993.93 | 64.72Average 64.7 Average | 15.15%Good 15.15% Good | 16.85%Good 16.85% Good | 0.30Excellent 0.3 Excellent | — — | — — | 0.04% |
13.9/100 | ₹805.50₹806 | ₹33947.05₹33947.05 | 166.00Average 166.0 Average | 11.01%Average 11.01% Average | 9.35%Poor 9.35% Poor | 1.44Average 1.4 Average | 3.71%Average 3.71% Average | 24.04%Excellent 24.04% Excellent | 0.00% | |
Dr. Agarwal's Health Care LimitedDr. Agarwal's H... AGARWALEYE • 544350 | 48.5/100 | ₹502.60₹503 | ₹15618.15₹15618.15 | 105.26Average 105.3 Average | 6.84%Poor 6.84% Poor | 10.16%Average 10.16% Average | 0.08Excellent 0.1 Excellent | — — | — — | 0.00% |
Rainbow Childrens Medicare LimitedRainbow Childre... RAINBOW • 543524 | 65.5/100 | ₹1458.70₹1459 | ₹15270.28₹15270.28 | 53.51Average 53.5 Average | 17.86%Good 17.86% Good | 18.10%Good 18.10% Good | 0.00Excellent 0.0 Excellent | — — | — — | 0.23% |
60/100 | ₹318.20₹318 | ₹9829.95₹9829.95 | 52.28Average 52.3 Average | 13.41%Average 13.41% Average | 15.25%Good 15.25% Good | 0.33Excellent 0.3 Excellent | — — | — — | 0.07% | |
Top Hospital Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Apollo Hospitals Enterprise Limited share price128448.55 Cr
- Max Healthcare Institute Limited share price107422.79 Cr
- Fortis Healthcare Limited share price73687.64 Cr
- Aster DM Quality Care Limited share price71917.90 Cr
- Narayana Hrudayalaya Ltd. share price41592.95 Cr
Lotus Eye Hospital and Institute Limited PE Ratio History
Historical price-to-earnings ratio for LOTUSEYE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.40 | ₹66.64 | 47.6x |
| FY 2023 | ₹1.96 | ₹83.40 | 42.6x |
| FY 2022 | ₹1.44 | ₹76.55 | 53.2x |
| FY 2021 | ₹0.75 | ₹51.90 | 69.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Lotus Eye Hospital and Institute Limited Dividend History
Annual cash dividends paid by LOTUSEYE — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.01 Cr |
| FY 2024 | ₹1.01 Cr |
| FY 2023 | ₹1.04 Cr |
| FY 2022 | ₹1.03 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Lotus Eye Hospital and Institute Limited Quarterly Performance
Latest quarterly metrics for LOTUSEYE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
26.19%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
12.65%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.66%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-44.79%
Compounded annual net profit growth over 5 years
Lotus Eye Hospital and Institute Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LOTUSEYE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Lotus Eye Hospital and Institute Limited Financial Statements
Annual income statement, balance sheet and cash flow for Lotus Eye Hospital and Institute Limited (LOTUSEYE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Lotus Eye Hospital and Institute Limited
About LOTUSEYE (Lotus Eye Hospital and Institute Limited)
Lotus Eye Hospital and Institute Ltd is a beacon of ophthalmic excellence, dedicated to preserving and enhancing vision through cutting-edge technology and compassionate care. Our ...state-of-the-art facilities house a comprehensive range of diagnostic and surgical equipment, enabling our team of highly skilled ophthalmologists to provide tailored treatments for a wide spectrum of eye conditions. From the subtle nuances of refractive errors to the complexities of retinal diseases, we approach each patient with a personalized strategy, prioritizing precision and optimal outcomes. We strive to create a comfortable and supportive environment, ensuring that every individual feels informed, empowered, and confident in their journey towards improved vision. Our commitment extends beyond clinical expertise to encompass a deep understanding of the emotional and psychological impact of vision impairment, fostering a holistic approach to eye care. Our hospital is renowned for its pioneering advancements in refractive surgery, offering a suite of sophisticated procedures designed to correct vision without the need for glasses or contact lenses. We utilize advanced techniques such as Femto LASIK, Contoura Vision, and ReLEx SMILE, tailoring each procedure to the unique characteristics of the patient's eye. In addition to refractive surgery, we specialize in the diagnosis and treatment of cataracts, glaucoma, and other vision-threatening conditions. Our surgeons are proficient in performing minimally invasive cataract surgery using advanced phacoemulsification and femtosecond laser technology. We provide comprehensive glaucoma management, utilizing the latest diagnostic tools and treatment modalities to preserve visual function and prevent further damage. Furthermore, Lotus Eye Hospital and Institute Ltd is committed to providing specialized care for children with eye disorders. Our pediatric ophthalmologists possess expertise in diagnosing and treating conditions such as strabismus (squint), amblyopia (lazy eye), and congenital cataracts. We understand the unique challenges of pediatric eye care and create a welcoming and child-friendly environment to ensure that young patients feel comfortable and at ease. Our institute is also dedicated to research and education, contributing to the advancement of ophthalmic knowledge and training the next generation of eye care professionals. We aim to be a center of excellence, continuously innovating and improving our services to provide the highest quality eye care to the community.
Company Details
Key Leadership
Corporate Events
LOTUSEYE Share Price: Frequently Asked Questions
What is the current share price of Lotus Eye Hospital and Institute Limited?
Lotus Eye Hospital and Institute Limited (LOTUSEYE) trades at ₹108.77 on NSE and BSE. Market cap ₹250.74 (Cr). Educational data only.
What is the P/E ratio of Lotus Eye Hospital and Institute Limited?
Lotus Eye Hospital and Institute Limited has a P/E of 1679.44x vs industry average 48.79x.
What is the Bull Run score for Lotus Eye Hospital and Institute Limited?
Lotus Eye Hospital and Institute Limited has a Bull Run score of 2.1/100 based on 25+ financial parameters.
Does Lotus Eye Hospital and Institute Limited pay dividends?
Lotus Eye Hospital and Institute Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Lotus Eye Hospital and Institute Limited?
Lotus Eye Hospital and Institute Limited has ROE of 0.13%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Lotus Eye Hospital and Institute Limited?
Lotus Eye Hospital and Institute Limited has debt-to-equity of 0.19.
Is Lotus Eye Hospital and Institute Limited a good investment?
Bull Run gives Lotus Eye Hospital and Institute Limited a score of 2.1/100. This is not investment advice — consult a SEBI-registered advisor.